Well, this certainly changes things. Seems like another story of ego and greed blowing up (potentially) good research.

The most useful quote in the article for me was from the sole administrator of the company that will be owning the license to the new drugs (if and when they materialize) and their comments were far more reserved about the 'cure'.

"The probability of this working out well isn’t high, to say the least, but if things go well, we estimate that in two or three years we could begin trials in human volunteers."